Synergy Pharmaceuticals Inc (SGYP) 4.34 $SGYP
Health Care Equities Analysis -- Research on Raptor Pharma, Intercept Pharma, KYTHERA Biopharma, and Synergy Pharma
PR Newswire - Tue Mar 25, 10:00AM CDT
On Monday, March 24, 2014, the NASDAQ Composite finished at 4,226.39, down 1.18%, the Dow Jones Industrial Average fell 0.16% to 16,276.69, and the S&P 500 closed at 1,857.44, down 0.49%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41%, and the same has declined 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), KYTHERA Biopharmaceuticals Inc. (NASDAQ: KYTH) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on RPTP, ICPT, KYTH and SGYP can be downloaded upon signing up at:
Synergy Pharmaceuticals Reports 2013 Fourth Quarter and Full-Year Financial Results
Business Wire - Mon Mar 17, 4:20PM CDT
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update for the fourth quarter and the year ended December 31, 2013. Synergy is developing plecanatide for the treatment of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C).
Synergy Pharmaceuticals Appoints Marino Garcia as Senior Vice President, Corporate Development
Business Wire - Thu Mar 13, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today the appointment of Marino Garcia as Senior Vice President, Corporate Development. In this newly created position reporting directly to the CEO, Mr. Garcia will play a critical leadership role in Synergy's strategic corporate planning and business development activities.
Synergy Pharmaceuticals, Inc. (SGYP) Looks Good: Stock Adds 8.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 7:44AM CST
Synergy Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Synergy Pharmaceuticals' Chief Scientific Officer to Present Plenary Lecture at the 2014 Southern Regional Meetings
Business Wire - Wed Feb 19, 5:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced its Chief Scientific Officer, Kunwar Shailubhai, Ph.D., M.B.A., will present a plenary lecture entitled, "Cyclic GMP: Understanding its Evolution and Clinical Implications in Gastroenterology," during the Southern Gut Club meeting being held at the InterContinental New Orleans on Thursday, February 20, at 7:00pm (EST).
Synergy Pharmaceuticals to Present at Two Upcoming Investment Conferences
Business Wire - Mon Feb 03, 5:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Chief Executive Officer, Gary S. Jacob, Ph.D., will present an overview of the company at two February investment conferences being held at the Waldorf Astoria in New York, N.Y.
Synergy Pharmaceuticals Inc's board sets ContraVir common stock distribution date of 18 February 2014
M2 - Wed Jan 29, 5:44AM CST
The board of directors of Synergy Pharmaceuticals Inc (NasdaqGS:SGYP), a developer of new drugs to treat gastrointestinal disorders, declared on Tuesday its final distribution ratio, as well as a pro rata dividend for the spin-off of the common shares of of its wholly-owned subsidiary, ContraVir Pharmaceuticals Inc.
Synergy Board of Directors Declares Dividend of ContraVir Common Stock
Business Wire - Tue Jan 28, 4:52PM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its board of directors has approved the final distribution ratio and declared a pro rata dividend for the spin-off of the shares of common stock of Synergy's wholly-owned subsidiary, ContraVir Pharmaceuticals, Inc. ("ContraVir"
.
NEC launches new DCMStar/ChainStore solution for international chain retailers
M2 - Wed Jan 15, 6:27AM CST
NEC Corporation (NEC; TSE: 6701) today announced the launch of a new addition to its lineup of DCMStar/ChainStore solutions for international retailers (chain stores) in the Asia Pacific (APAC) region and elsewhere. Primary functions of the new product include the provision of product order recommendations, a function providing real-time access to sales and inventory information from each store, and a CRM function that can be used to implement a wide variety of point card services.
2013 Report on the International Push to Talk Telemedicine and M-Health Convergence - Forecasts to 2019
M2 - Wed Jan 15, 6:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/m7mhgx/push_to_talk) has announced the addition of a new report "2013 Report on the International Push to Talk Telemedicine and M-Health Convergence - Forecasts to 2019" to their offering. PTT telemedicine markets are poised to achieve significant growth as the existing telemedicine systems merge with the smart phone systems of engagement to provide a way to improve clinical care delivery to patients with chronic disease, decreasing hospitalizations and visits to the emergency room. There is a convergence of telemedicine and m-health as the patients become more responsible for their own care delivery and their own health. There is a convergence of telemedicine and m-health as the patient uses push to talk devices in telemonitoring situations where the sensor data is transmitted to a facility, encouraging the patient to become more responsible for their own care delivery and their own health. Healthcare patient, physician, and facility decision support markets are forecast based n the broad availability of smartphones combined with the IBM Watson technology that Watson offers Interactive Care Insights for Oncology. Telemedicine push to talk PTT dedicated device and software markets at $214 million in 2012 are anticipated to reach $4.4 billion by 2019. M-Health markets related to telemedicine at $1.4 billion are anticipated to reach $1.5 trillion by 2019 due to the leveraging of 8.5 billion smart phones and 5 billion connected tablet devices all over the world. Key Topics Covered: 1. Telemedicine and M-Health Market Description and Market Dynamics 2. Tele-Medicine / M-Health Market Shares and Market Forecasts 3. Telemedicine / M-Health Product Description 4 . Tele-Monitor Technology 5. Telemedicine / M-Health Company Profiles Companies Mentioned: - AT&T - Apple - Biotronik - Bosch Group - CMO, The Care Management Company - Debiotech - Family Home Care - FuzeBox - Glaxo Smith Kline - Google - Honeywell - IBM - Infopia - JSC CEM Technology - KSB Home Health - LG - Logitech - Medtronic - Microsoft - Nonin Medical, Inc. - Partners Healthcare - Philips - REACH Health, Inc. - RS TechMedic BV - Royal Philips Revenue - STMicroelectronics - Samsung - Sandata Technologies, Inc. - TeleAtrics - University of Houston - VIDAVO S.A - Vodafone - WellPoint: Independent Licensee Blue Cross and Blue Shield Association For more information visit http://www.researchandmarkets.com/research/m7...sh_to_talk
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
Synergy Pharmaceuticals Named to NASDAQ Global Select Market
Business Wire - Thu Jan 02, 4:59AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced listing of the company's common stock has been transferred to the NASDAQ Global Select Market, the highest of the three market tiers at NASDAQ. Listing on the NASDAQ Global Select Market is reserved for companies that meet the highest quantitative and qualitative listing standards, reflecting their demonstrated commitments to leadership and good governance.
Synergy Pharma Progresses with Plecanatide - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 26, 3:30PM CST
Synergy Pharma completed the enrolment process for its phase IIb clinical study on plecanatide.
Synergy Pharmaceuticals Inc concludes patient enrollment under plecanatide Phase 2b trial in IBS-C patients
M2 - Tue Dec 24, 8:39AM CST
Biopharmaceutical company Synergy Pharmaceuticals Inc (NasdaqGM:SGYP) said on Tuesday that it has completed patient enrollment in its plecanatide phase 2b clinical trial in irritable bowel syndrome with constipation (IBS-C).
Why You Need To Watch Johnson & Johnson, Synergy, Sagent, and Supernus This Morning
Leo Sun, The Motley Fool - Motley Fool - Tue Dec 24, 8:04AM CST
Follow @leokornsun // full story)
Synergy Pharmaceuticals Catches Eyes: Stock Jumps 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 24, 6:44AM CST
Synergy Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 9% on the day
Synergy Pharmaceuticals Closes Enrollment for Plecanatide Phase 2b Trial in Patients with IBS-C
Business Wire - Tue Dec 24, 4:59AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced it has closed patient enrollment in its plecanatide phase 2b clinical trial in irritable bowel syndrome with constipation (IBS-C).
Durata Therapeutics (DRTX) in Focus: Stock Up 7.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 29, 6:44AM CST
Durata Therapeutics, Inc.was a big mover last session, as the company saw its shares jump nearly 8% on the day.
Inflammatory Bowel Disease - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/g29c7q/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H2 2013" report to their offering. 'Inflammatory Bowel Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Scope - A snapshot of the global therapeutic scenario for Inflammatory Bowel Disease. - A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Inflammatory Bowel Disease pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Introduction Inflammatory Bowel Disease Overview Therapeutics Development Companies Involved in Inflammatory Bowel Disease Therapeutics Development Inflammatory Bowel Disease - Therapeutics Assessment Drug Profiles Appendix Companies Mentioned - 4SC - AlbireoPharma - Addex Pharmaceuticals - Basilea Pharmaceutica - Biotec Pharmacon - Compugen - Emergent BioSolutions - Eisai - Ferring Pharmaceuticals - GlaxoSmithKline - Indus Biotech Private Limited - Inotek Pharmaceuticals - Jenrin Discovery - Johnson & Johnson - KYORIN Pharmaceutical - Karo Bio - Lycera - Morria Biopharmaceuticals - Mitsubishi Tanabe Pharma - N30 Pharmaceuticals - Nephrx Corporation - Ono Pharmaceutical - Onyx Pharmaceuticals - PepTcell Limited - Paratek Pharmaceuticals - RaQualia Pharma - Rigel Pharmaceuticals - Santarus, Inc. - Synergy Pharmaceuticals - TiGenix NV - Upsher-Smith Laboratories - VentiRx Pharmaceuticals - Ventria Bioscience - Vitae Pharmaceuticals - Zealand Pharma A/S - iCo Therapeutics For more information visit http://www.researchandmarkets.com/research/g2...flammatory
Synergy Pharma's Q3 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 15, 8:20AM CST
Synergy Pharma reported third quarter 2013 loss of 15 cents per share, which remained flat year over year
Health Care Equities Analysis -- Research on Raptor Pharma, Intercept Pharma, KYTHERA Biopharma, and Synergy Pharma
PR Newswire - Tue Mar 25, 10:00AM CDT
On Monday, March 24, 2014, the NASDAQ Composite finished at 4,226.39, down 1.18%, the Dow Jones Industrial Average fell 0.16% to 16,276.69, and the S&P 500 closed at 1,857.44, down 0.49%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41%, and the same has declined 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), KYTHERA Biopharmaceuticals Inc. (NASDAQ: KYTH) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on RPTP, ICPT, KYTH and SGYP can be downloaded upon signing up at:
Synergy Pharmaceuticals Reports 2013 Fourth Quarter and Full-Year Financial Results
Business Wire - Mon Mar 17, 4:20PM CDT
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update for the fourth quarter and the year ended December 31, 2013. Synergy is developing plecanatide for the treatment of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C).
Synergy Pharmaceuticals Appoints Marino Garcia as Senior Vice President, Corporate Development
Business Wire - Thu Mar 13, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today the appointment of Marino Garcia as Senior Vice President, Corporate Development. In this newly created position reporting directly to the CEO, Mr. Garcia will play a critical leadership role in Synergy's strategic corporate planning and business development activities.
Synergy Pharmaceuticals, Inc. (SGYP) Looks Good: Stock Adds 8.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 7:44AM CST
Synergy Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Synergy Pharmaceuticals' Chief Scientific Officer to Present Plenary Lecture at the 2014 Southern Regional Meetings
Business Wire - Wed Feb 19, 5:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced its Chief Scientific Officer, Kunwar Shailubhai, Ph.D., M.B.A., will present a plenary lecture entitled, "Cyclic GMP: Understanding its Evolution and Clinical Implications in Gastroenterology," during the Southern Gut Club meeting being held at the InterContinental New Orleans on Thursday, February 20, at 7:00pm (EST).
Synergy Pharmaceuticals to Present at Two Upcoming Investment Conferences
Business Wire - Mon Feb 03, 5:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Chief Executive Officer, Gary S. Jacob, Ph.D., will present an overview of the company at two February investment conferences being held at the Waldorf Astoria in New York, N.Y.
Synergy Pharmaceuticals Inc's board sets ContraVir common stock distribution date of 18 February 2014
M2 - Wed Jan 29, 5:44AM CST
The board of directors of Synergy Pharmaceuticals Inc (NasdaqGS:SGYP), a developer of new drugs to treat gastrointestinal disorders, declared on Tuesday its final distribution ratio, as well as a pro rata dividend for the spin-off of the common shares of of its wholly-owned subsidiary, ContraVir Pharmaceuticals Inc.
Synergy Board of Directors Declares Dividend of ContraVir Common Stock
Business Wire - Tue Jan 28, 4:52PM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its board of directors has approved the final distribution ratio and declared a pro rata dividend for the spin-off of the shares of common stock of Synergy's wholly-owned subsidiary, ContraVir Pharmaceuticals, Inc. ("ContraVir"
. NEC launches new DCMStar/ChainStore solution for international chain retailers
M2 - Wed Jan 15, 6:27AM CST
NEC Corporation (NEC; TSE: 6701) today announced the launch of a new addition to its lineup of DCMStar/ChainStore solutions for international retailers (chain stores) in the Asia Pacific (APAC) region and elsewhere. Primary functions of the new product include the provision of product order recommendations, a function providing real-time access to sales and inventory information from each store, and a CRM function that can be used to implement a wide variety of point card services.
2013 Report on the International Push to Talk Telemedicine and M-Health Convergence - Forecasts to 2019
M2 - Wed Jan 15, 6:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/m7mhgx/push_to_talk) has announced the addition of a new report "2013 Report on the International Push to Talk Telemedicine and M-Health Convergence - Forecasts to 2019" to their offering. PTT telemedicine markets are poised to achieve significant growth as the existing telemedicine systems merge with the smart phone systems of engagement to provide a way to improve clinical care delivery to patients with chronic disease, decreasing hospitalizations and visits to the emergency room. There is a convergence of telemedicine and m-health as the patients become more responsible for their own care delivery and their own health. There is a convergence of telemedicine and m-health as the patient uses push to talk devices in telemonitoring situations where the sensor data is transmitted to a facility, encouraging the patient to become more responsible for their own care delivery and their own health. Healthcare patient, physician, and facility decision support markets are forecast based n the broad availability of smartphones combined with the IBM Watson technology that Watson offers Interactive Care Insights for Oncology. Telemedicine push to talk PTT dedicated device and software markets at $214 million in 2012 are anticipated to reach $4.4 billion by 2019. M-Health markets related to telemedicine at $1.4 billion are anticipated to reach $1.5 trillion by 2019 due to the leveraging of 8.5 billion smart phones and 5 billion connected tablet devices all over the world. Key Topics Covered: 1. Telemedicine and M-Health Market Description and Market Dynamics 2. Tele-Medicine / M-Health Market Shares and Market Forecasts 3. Telemedicine / M-Health Product Description 4 . Tele-Monitor Technology 5. Telemedicine / M-Health Company Profiles Companies Mentioned: - AT&T - Apple - Biotronik - Bosch Group - CMO, The Care Management Company - Debiotech - Family Home Care - FuzeBox - Glaxo Smith Kline - Google - Honeywell - IBM - Infopia - JSC CEM Technology - KSB Home Health - LG - Logitech - Medtronic - Microsoft - Nonin Medical, Inc. - Partners Healthcare - Philips - REACH Health, Inc. - RS TechMedic BV - Royal Philips Revenue - STMicroelectronics - Samsung - Sandata Technologies, Inc. - TeleAtrics - University of Houston - VIDAVO S.A - Vodafone - WellPoint: Independent Licensee Blue Cross and Blue Shield Association For more information visit http://www.researchandmarkets.com/research/m7...sh_to_talk
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
Synergy Pharmaceuticals Named to NASDAQ Global Select Market
Business Wire - Thu Jan 02, 4:59AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced listing of the company's common stock has been transferred to the NASDAQ Global Select Market, the highest of the three market tiers at NASDAQ. Listing on the NASDAQ Global Select Market is reserved for companies that meet the highest quantitative and qualitative listing standards, reflecting their demonstrated commitments to leadership and good governance.
Synergy Pharma Progresses with Plecanatide - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 26, 3:30PM CST
Synergy Pharma completed the enrolment process for its phase IIb clinical study on plecanatide.
Synergy Pharmaceuticals Inc concludes patient enrollment under plecanatide Phase 2b trial in IBS-C patients
M2 - Tue Dec 24, 8:39AM CST
Biopharmaceutical company Synergy Pharmaceuticals Inc (NasdaqGM:SGYP) said on Tuesday that it has completed patient enrollment in its plecanatide phase 2b clinical trial in irritable bowel syndrome with constipation (IBS-C).
Why You Need To Watch Johnson & Johnson, Synergy, Sagent, and Supernus This Morning
Leo Sun, The Motley Fool - Motley Fool - Tue Dec 24, 8:04AM CST
Follow @leokornsun // full story)
Synergy Pharmaceuticals Catches Eyes: Stock Jumps 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 24, 6:44AM CST
Synergy Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 9% on the day
Synergy Pharmaceuticals Closes Enrollment for Plecanatide Phase 2b Trial in Patients with IBS-C
Business Wire - Tue Dec 24, 4:59AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced it has closed patient enrollment in its plecanatide phase 2b clinical trial in irritable bowel syndrome with constipation (IBS-C).
Durata Therapeutics (DRTX) in Focus: Stock Up 7.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 29, 6:44AM CST
Durata Therapeutics, Inc.was a big mover last session, as the company saw its shares jump nearly 8% on the day.
Inflammatory Bowel Disease - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/g29c7q/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H2 2013" report to their offering. 'Inflammatory Bowel Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Scope - A snapshot of the global therapeutic scenario for Inflammatory Bowel Disease. - A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Inflammatory Bowel Disease pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Introduction Inflammatory Bowel Disease Overview Therapeutics Development Companies Involved in Inflammatory Bowel Disease Therapeutics Development Inflammatory Bowel Disease - Therapeutics Assessment Drug Profiles Appendix Companies Mentioned - 4SC - AlbireoPharma - Addex Pharmaceuticals - Basilea Pharmaceutica - Biotec Pharmacon - Compugen - Emergent BioSolutions - Eisai - Ferring Pharmaceuticals - GlaxoSmithKline - Indus Biotech Private Limited - Inotek Pharmaceuticals - Jenrin Discovery - Johnson & Johnson - KYORIN Pharmaceutical - Karo Bio - Lycera - Morria Biopharmaceuticals - Mitsubishi Tanabe Pharma - N30 Pharmaceuticals - Nephrx Corporation - Ono Pharmaceutical - Onyx Pharmaceuticals - PepTcell Limited - Paratek Pharmaceuticals - RaQualia Pharma - Rigel Pharmaceuticals - Santarus, Inc. - Synergy Pharmaceuticals - TiGenix NV - Upsher-Smith Laboratories - VentiRx Pharmaceuticals - Ventria Bioscience - Vitae Pharmaceuticals - Zealand Pharma A/S - iCo Therapeutics For more information visit http://www.researchandmarkets.com/research/g2...flammatory
Synergy Pharma's Q3 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 15, 8:20AM CST
Synergy Pharma reported third quarter 2013 loss of 15 cents per share, which remained flat year over year
